Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1991 Oct;50(10):663–665. doi: 10.1136/ard.50.10.663

Treatment of osteoporosis: current and future.

M D Stone 1, D J Hosking 1
PMCID: PMC1004523  PMID: 1958084

Full text

PDF
663

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams B., Parker J. D. Maternal weight gain in women with good pregnancy outcome. Obstet Gynecol. 1990 Jul;76(1):1–7. [PubMed] [Google Scholar]
  2. Boyce B. F., Smith L., Fogelman I., Johnston E., Ralston S., Boyle I. T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet. 1984 Apr 14;1(8381):821–824. doi: 10.1016/s0140-6736(84)92272-4. [DOI] [PubMed] [Google Scholar]
  3. Canalis E., McCarthy T., Centrella M. Growth factors and the regulation of bone remodeling. J Clin Invest. 1988 Feb;81(2):277–281. doi: 10.1172/JCI113318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Christensen M. S., Hagen C., Christiansen C., Transbøl I. Dose-response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol. 1982 Dec 15;144(8):873–879. doi: 10.1016/0002-9378(82)90176-4. [DOI] [PubMed] [Google Scholar]
  5. Christiansen C., Christensen M. S., McNair P., Hagen C., Stocklund K. E., Transbøl I. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest. 1980 Aug;10(4):273–279. doi: 10.1111/j.1365-2362.1980.tb00033.x. [DOI] [PubMed] [Google Scholar]
  6. Christiansen C., Lindsay R. Estrogens, bone loss and preservation. Osteoporos Int. 1990 Oct;1(1):7–13. doi: 10.1007/BF01880410. [DOI] [PubMed] [Google Scholar]
  7. Christiansen C., Riis B. J. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women. J Clin Endocrinol Metab. 1990 Oct;71(4):836–841. doi: 10.1210/jcem-71-4-836. [DOI] [PubMed] [Google Scholar]
  8. Coope J. Perimenopausal women's views on hormone replacement therapy. BMJ. 1990 Jun 9;300(6738):1526–1526. doi: 10.1136/bmj.300.6738.1526-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Coulter A., McPherson K., Vessey M. Do British women undergo too many or too few hysterectomies? Soc Sci Med. 1988;27(9):987–994. doi: 10.1016/0277-9536(88)90289-4. [DOI] [PubMed] [Google Scholar]
  10. Dempster D. W., Shane E., Horbert W., Lindsay R. A simple method for correlative light and scanning electron microscopy of human iliac crest bone biopsies: qualitative observations in normal and osteoporotic subjects. J Bone Miner Res. 1986 Feb;1(1):15–21. doi: 10.1002/jbmr.5650010105. [DOI] [PubMed] [Google Scholar]
  11. Draper J., Roland M. Perimenopausal women's views on taking hormone replacement therapy to prevent osteoporosis. BMJ. 1990 Mar 24;300(6727):786–788. doi: 10.1136/bmj.300.6727.786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ettinger B., Genant H. K., Cann C. E. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med. 1985 Mar;102(3):319–324. doi: 10.7326/0003-4819-102-3-319. [DOI] [PubMed] [Google Scholar]
  13. Frijlink W. B., Bijvoet O. L., te Velde J., Heynen G. Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):799–803. doi: 10.1016/s0140-6736(79)91318-7. [DOI] [PubMed] [Google Scholar]
  14. Gerster J. C., Charhon S. A., Jaeger P., Boivin G., Briancon D., Rostan A., Baud C. A., Meunier P. J. Bilateral fractures of femoral neck in patients with moderate renal failure receiving fluoride for spinal osteoporosis. Br Med J (Clin Res Ed) 1983 Sep 10;287(6394):723–725. doi: 10.1136/bmj.287.6394.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hahn R. G. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol. 1989 Dec;161(6 Pt 2):1854–1858. doi: 10.1016/s0002-9378(89)80006-7. [DOI] [PubMed] [Google Scholar]
  16. Hodsman A. B., Drost D. J. The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride. J Clin Endocrinol Metab. 1989 Nov;69(5):932–938. doi: 10.1210/jcem-69-5-932. [DOI] [PubMed] [Google Scholar]
  17. Howe H. L. Age-specific hysterectomy and oophorectomy prevalence rates and the risks for cancer of the reproductive system. Am J Public Health. 1984 Jun;74(6):560–563. doi: 10.2105/ajph.74.6.560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lindsay R., Hart D. M., Clark D. M. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984 Jun;63(6):759–763. [PubMed] [Google Scholar]
  19. Lindsay R., Hart D. M., Forrest C., Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980 Nov 29;2(8205):1151–1154. doi: 10.1016/s0140-6736(80)92592-1. [DOI] [PubMed] [Google Scholar]
  20. Lindsay R., Hart D. M., Purdie D., Ferguson M. M., Clark A. S., Kraszewski A. Comparative effects of oestrogen and a progestogen on bone loss in postmenopausal women. Clin Sci Mol Med. 1978 Feb;54(2):193–195. doi: 10.1042/cs0540193. [DOI] [PubMed] [Google Scholar]
  21. Magos A. L., Brincat M., Studd J. W., Wardle P., Schlesinger P., O'Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol. 1985 Apr;65(4):496–499. [PubMed] [Google Scholar]
  22. Mamelle N., Meunier P. J., Dusan R., Guillaume M., Martin J. L., Gaucher A., Prost A., Zeigler G., Netter P. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet. 1988 Aug 13;2(8607):361–365. doi: 10.1016/s0140-6736(88)92834-6. [DOI] [PubMed] [Google Scholar]
  23. McCloskey E. V., Yates A. J., Beneton M. N., Galloway J., Harris S., Kanis J. A. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone. 1987;8 (Suppl 1):S35–S41. [PubMed] [Google Scholar]
  24. Nadalini V. F., Giglio C., Bruttini G. P., Medica M., Piccardo M., Ruggeri C. Fluoroscopically guided skinny-needle aspirative biopsy in normal and suspected lymph nodes in urologic cancer. Urol Int. 1983;38(5):317–319. doi: 10.1159/000280914. [DOI] [PubMed] [Google Scholar]
  25. Pacifici R., McMurtry C., Vered I., Rupich R., Avioli L. V. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. J Clin Endocrinol Metab. 1988 Apr;66(4):747–753. doi: 10.1210/jcem-66-4-747. [DOI] [PubMed] [Google Scholar]
  26. Paganini-Hill A., Ross R. K., Gerkins V. R., Henderson B. E., Arthur M., Mack T. M. Menopausal estrogen therapy and hip fractures. Ann Intern Med. 1981 Jul;95(1):28–31. doi: 10.7326/0003-4819-95-1-28. [DOI] [PubMed] [Google Scholar]
  27. Pak C. Y., Sakhaee K., Zerwekh J. E., Parcel C., Peterson R., Johnson K. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab. 1989 Jan;68(1):150–159. doi: 10.1210/jcem-68-1-150. [DOI] [PubMed] [Google Scholar]
  28. Parfitt A. M. Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. Clin Obstet Gynecol. 1987 Dec;30(4):789–811. doi: 10.1097/00003081-198712000-00004. [DOI] [PubMed] [Google Scholar]
  29. Quarles L. D., Murphy G., Vogler J. B., Drezner M. K. Aluminum-induced neo-osteogenesis: a generalized process affecting trabecular networking in the axial skeleton. J Bone Miner Res. 1990 Jun;5(6):625–635. doi: 10.1002/jbmr.5650050612. [DOI] [PubMed] [Google Scholar]
  30. Raisz L. G. Local and systemic factors in the pathogenesis of osteoporosis. N Engl J Med. 1988 Mar 31;318(13):818–828. doi: 10.1056/NEJM198803313181305. [DOI] [PubMed] [Google Scholar]
  31. Ravnikar V. A. Compliance with hormone therapy. Am J Obstet Gynecol. 1987 May;156(5):1332–1334. doi: 10.1016/0002-9378(87)90173-6. [DOI] [PubMed] [Google Scholar]
  32. Reid I. R., Schooler B. A., Stewart A. W. Prevention of glucocorticoid-induced osteoporosis. J Bone Miner Res. 1990 Jun;5(6):619–623. doi: 10.1002/jbmr.5650050611. [DOI] [PubMed] [Google Scholar]
  33. Riggs B. L., Hodgson S. F., O'Fallon W. M., Chao E. Y., Wahner H. W., Muhs J. M., Cedel S. L., Melton L. J., 3rd Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990 Mar 22;322(12):802–809. doi: 10.1056/NEJM199003223221203. [DOI] [PubMed] [Google Scholar]
  34. Storm T., Thamsborg G., Steiniche T., Genant H. K., Sørensen O. H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990 May 3;322(18):1265–1271. doi: 10.1056/NEJM199005033221803. [DOI] [PubMed] [Google Scholar]
  35. Valkema R., Vismans F. J., Papapoulos S. E., Pauwels E. K., Bijvoet O. L. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989 Jan;5(2):183–192. doi: 10.1016/0169-6009(89)90095-0. [DOI] [PubMed] [Google Scholar]
  36. Wallace W. A., Price V. H., Elliot C. A., MacPherson M. B., Scott B. W. Hormone replacement therapy acceptability to Nottingham post-menopausal women with a risk factor for osteoporosis. J R Soc Med. 1990 Nov;83(11):699–701. doi: 10.1177/014107689008301109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Weiss N. S., Ure C. L., Ballard J. H., Williams A. R., Daling J. R. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med. 1980 Nov 20;303(21):1195–1198. doi: 10.1056/NEJM198011203032102. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES